The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)

Launched by KING'S COLLEGE HOSPITAL NHS TRUST · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating the presence and effects of a special type of fat called metabolically active brown adipose tissue (aBAT) in patients with pheochromocytoma or paraganglioma, which are tumors that can produce hormones affecting blood pressure and metabolism. The researchers want to understand how often aBAT is found in these patients and how it relates to their health, hormone levels, and other factors. They hope to determine if higher levels of aBAT could be linked to more severe symptoms and poorer outcomes for patients.

To participate in this study, individuals must have been diagnosed with either pheochromocytoma or paraganglioma and have undergone a specific imaging test called FDG-PET as part of their staging process. The trial is open to patients aged 18 and older, regardless of gender. Participants will help researchers learn more about how activated brown fat interacts with these tumors, which could ultimately lead to better care and understanding of these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with confirmed pheochromocytoma or paraganglioma who have undergone a FDG-PET as part of staging process.
• Exclusion Criteria:
• • Patients with any other neoplasm other than pheochromocytoma or paraganglioma